Evidence map›Paper›PMID 30254477›Full record

ReviewInfection and drug resistance2018

Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant

Lindsay A Petty, Oryan Henig, Twisha S Patel, Jason M Pogue, Keith S Kaye

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Infection and drug resistance, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 2 pooled it
4.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 92 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. StudiesAntimicrobial agents and chemotherapy · 2025
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Class C β-Lactamases: Molecular Characteristics.Clinical microbiology reviews · 2022
    Review
  14. The biogenesis of β-lactamase enzymes.Microbiology (Reading, England) · 2022
    Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Lindsay A PettyDepartment of Internal Medicine, Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, MI, USA, pettyl@med.umich.edu.
Oryan HenigDepartment of Internal Medicine, Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, MI, USA, pettyl@med.umich.edu.
Twisha S PatelDepartment of Pharmacy Services, University of Michigan Hospitals and Health Centers, Ann Arbor, MI, USA.
Jason M PogueDepartment of Pharmacy Services, Sinai-Grace Hospital, Detroit Medical Center, Detroit, MI, USA.
Keith S KayeDepartment of Internal Medicine, Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, MI, USA, pettyl@med.umich.edu.
University of Michigan · USDetroit Medical Center · US

Funding

Optimizing Clinical Use of Polymyxin B: Teaching an Old Drug to Treat SuperbugsR01AI119446 · NIAID · WAYNE STATE UNIVERSITY · PI LI, JIAN, POGUE, JASON MICHAEL · 2015 to 2019
$5.0M
NIAID NIH HHS R01 AI119446
6 · The paper itself

Abstract

There has been a worldwide increase in infections caused by drug-resistant Gram-negative pathogens, including carbapenem-resistant

Indexed as

carbapenemaseCREKPCmeropenemUTIvaborbactam

Identifiers

PMID30254477
PMCPMC6140735
OpenAlexW2889629084

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.